Is MK-677 a peptide?

What MK-677 means

MK-677 and ibutamoren are names for the same compound. The U.S. Food and Drug Administration, or FDA, uses both names in its September 23, 2025, safety notice.

A peptide contains two or more amino-acid units joined by peptide bonds. That definition describes chemical structure. The receptor study classifies MK-677 as nonpeptide, although it acts on the same receptor as peptide compounds.

Researchers describe it as a growth hormone secretagogue. A secretagogue is a substance that causes cells to release another substance. Here, the term refers to growth hormone release. Secretagogue names an effect, so it does not place MK-677 in a chemical class.

A heading can group several compounds together. That heading, or a shared biological effect, cannot establish that all listed compounds are peptides.

What the classification study shows

A 2005 study by Holst and colleagues compared MK-677 with peptide compounds at the ghrelin receptor. Its laboratory tests measured receptor binding and signals within cells. The authors explicitly classified MK-677 as nonpeptide.

Different compounds can act on the same receptor and still differ in structure, effects in people, and safety profile. These laboratory results do not establish a treatment benefit.

Earlier research by Patchett and colleagues, published in 1995, used the names L-163,191 and MK-0677. It studied hormone release in rat cells and dogs. Oral administration in those experiments does not establish human benefit or a safer route.

Keep the compound separate from the product

The name on a label does not show that a product matches the material used in a study. Evidence must fit the exact substance, formulation, route, and population.

Some records name ibutamoren mesylate. For example, the hip-fracture trial and FDA compounding table use that name. Keep those records tied to the material they identify. Do not assume that another formulation or finished product is equivalent.

In its September 23, 2025, notice, FDA reported finding undeclared ibutamoren in Agebox iKids Growth Day Formula. That finding applies to the tested product and does not establish what any other product contains.

The same notice states that ibutamoren is not FDA approved. It also says that its safety and effectiveness have not been established. The notice was rechecked on September 11, 2026. It is a dated U.S. statement and does not review the laws of every country.

What the safety evidence can tell you

FDA identifies a potential congestive heart-failure risk for ibutamoren mesylate in certain patients. Heart failure means the heart cannot pump blood as well as the body needs. FDA links this concern to a trial in people recovering from hip fracture.

The 2011 report by Adunsky and colleagues describes a randomized, placebo-controlled trial in 123 older hip-fracture patients. Its outcomes included physical function and a blood marker related to growth hormone. The report gives results at 24 weeks.

The authors report that the trial stopped early after a heart-failure safety signal. The blood marker rose, but most measures of physical function did not improve.

These findings do not give a reliable risk rate for a different population or product, and they do not show that other people are safe. A nonpeptide classification does not remove the need for safety evidence.

Why a shared receptor cannot define a peptide

The receptor study compares peptide and nonpeptide compounds that act at the ghrelin receptor. A receptor is a target in a cell. Its response describes an interaction, not the arrangement of atoms in every compound that reaches it. IUPAC uses peptide bonds between amino-acid units to define a peptide. The study calls MK-677 nonpeptide even though it also activates the receptor. Both statements can be true because they answer different questions.

This distinction also explains growth hormone secretagogue. The term describes a hormone-release effect. It includes more than one structural class. Calling MK-677 a secretagogue does not turn it into GHRP-6 or another peptide. To assess a statement, identify the exact test compound in the paper, then separate its chemical class from its measured receptor response. A shared target is a reason to compare results carefully, not to merge the materials.

The older Patchett paper used L-163,191 and MK-0677 in its research history. Names and codes can change across papers. A reader should confirm that a citation discusses the intended compound before accepting a claim about ibutamoren. The early experiments used rat cells and dogs, so the record also cannot be presented as a human treatment result.

Read the human trial by its outcomes

The hip-fracture trial compared ibutamoren mesylate with placebo in 123 older patients recovering from a fracture. It measured insulin-like growth factor 1, or IGF-1, in blood and several tests of physical function. The blood marker increased. Most functional measures did not improve. That difference matters: a biological marker can move while the outcome that matters to patients remains uncertain or unchanged.

The report also says the trial ended early because of a congestive heart-failure safety signal in a limited number of patients. An early stop can restrict what the trial can establish about benefit and harm. It is not sound to ignore the safety signal because the marker rose, or to calculate a general risk rate for other populations from this brief abstract. FDA cites a potential heart-failure risk in certain patients.

This trial did not turn MK-677 into a peptide. Its purpose was to test outcomes and safety for a named material in a defined population. If a later claim concerns healthy adults, athletes, or another product, the population and material have changed. The original result should remain attached to hip-fracture patients and the outcomes actually measured.

Do not let a label close the evidence gap

FDA found undeclared ibutamoren in one named consumer product. The finding is concrete evidence about that product. It does not prove that another product contains ibutamoren, lacks it, or matches a research compound. A research paper, a product label, and a regulator's test result are three different records. A credible claim should name which one supports each sentence.

The FDA notice says ibutamoren is not approved and its safety and effectiveness have not been established. That dated U.S. status is separate from the chemical answer. Nonpeptide does not mean safe, and a hormone marker does not mean effective. The useful conclusion is limited: MK-677 is a nonpeptide ghrelin-receptor compound with research and safety records that require careful, exact matching.

What was reviewed

Classification does not establish benefits for muscle growth, recovery, or aging. Each claim needs separate evidence.

The sources reviewed were study abstracts, FDA records, and the IUPAC definition. Full study methods, all adverse-event tables, and complete conflict disclosures were not reviewed. These records cannot verify an online product's identity or quality.